ERFINDERGEMEINSCHAFT UROPEP GbR v. Eli Lilly and Company
2:15-cv-01202
Overview
Parties
Mediator
Defendant
Plaintiff
ERFINDERGEMEINSCHAFT UROPEP GbR NPE (Individual / Inventor)
Represented By
0 Attorneys ListedCourt & Judges
Court
District Court, E.D. Texas (txed)
Presiding Judge
Global Patent Family Cross-Litigation Radar
CasLoc 360Β° Radar 8 Family MembersMulti-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions
| Jurisdiction | Publication Number | Relationship | Official Record |
|---|---|---|---|
| πΊπΈ United States | Asserted | US Continuation / Sibling | View Official Patent → |
| πΊπΈ United States | US Continuation / Sibling | View Official Patent → | |
| πΊπΈ United States | US Continuation / Sibling | View Official Patent → | |
| πΊπΈ United States | US Continuation / Sibling | View Official Patent → | |
| πΊπΈ United States | US Continuation / Sibling | View Official Patent → | |
| πΊπΈ United States | US Continuation / Sibling | View Official Patent → | |
| πΊπΈ United States | US Continuation / Sibling | View Official Patent → | |
| πΊπΈ United States | US Continuation / Sibling | View Official Patent → |
Alvogen Pine Brook LLC et al. v. Celgene Corporation
Patents Involved
There are 7 patents involved in this case.
| Patent Asset | Filing & Issue Date | Expiration & Term Status | External Links |
|---|---|---|---|
|
US9393238
Methods for treating non-hodgkin's lymphoma with 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione in combination with a second active agent
|
Filed: 2014-12-08
Issued: 2016-07-19
|
Active (8.0 yrs remaining)
Expires: 2034-12-08
|
|
|
US5674887
Prevention of bone resorption
|
Filed: 1995-02-22
Issued: 1997-10-07
|
Expired (Term Ended)
Expires: 2015-02-22
|
|
|
US6451807
Methods of treating sexual dysfunction in an individual suffering from a retinal disease, class 1 congestive heart failure, or myocardial infarction using a PDE5 inhibitor
|
Filed: 2000-04-26
Issued: 2002-09-17
|
Expired (Term Ended)
Expires: 2020-04-26
|
|
|
US5393755
Polycyclic guanine derivatives
|
Filed: 1991-06-20
Issued: 1995-02-28
|
Expired (Term Ended)
Expires: 2011-06-20
|
|
|
USRE38115
Dextromethorphan and an oxidase inhibitor for treating intractable conditions
|
Filed: 1994-09-22
Issued: 2003-05-06
|
Expired (Term Ended)
Expires: 2014-09-22
|
|
|
US6245802
Method for treating pain
|
Filed: 1999-11-11
Issued: 2001-06-12
|
Expired (Term Ended)
Expires: 2019-11-11
|
|
|
US6492371
Use of cyclic GMP-specific phosphodiesterase inhibitors for treatment of Parkinson's Disease
|
Filed: 2001-11-21
Issued: 2002-12-10
|
Expired (Term Ended)
Expires: 2021-11-21
|
Patent Enforceability & Injunction Risk Assessment
Active Threat β Patent is within enforceable statutory term; injunctive relief viable.
Standard Statutory Term β No obviousness-type double patenting noted.
Under 35 U.S.C. Β§ 286, damages cannot accrue for infringement prior to 6 years before filing. 4th Year Maintenance Fee Paid (8th Year Window Upcoming).
Procedural Motions & Interlocutory Orders
Total Motions
643
Dispositive
366
Granted
43
Denied
5
Pending / Review
83
Motions by Category
Key Dispositive Motions & Rulings